# A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

> **NCT07148180** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jacqueline Garcia, MD** · enrollment: 31 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Leukemia
- Blood Cancer
- Blood Cancers

## Interventions

- **DRUG:** Tagraxofusp
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07148180
- **Lead sponsor:** Jacqueline Garcia, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148180, "A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07148180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*